31575-93-6

Usage

Uses

Used in Pharmaceutical Industry:
Heraclenol is used as a therapeutic agent for its potential anti-inflammatory, antioxidant, and antimicrobial properties, targeting various conditions including cancer, cardiovascular diseases, and diabetes.
Used in Cosmetic Industry:
Heraclenol is used as a skin-protective and anti-aging ingredient, leveraging its beneficial effects on the skin to promote health and reduce signs of aging.
Used in Antimicrobial Applications:
Heraclenol is employed as an antimicrobial agent, utilizing its natural properties to combat microbial infections and promote overall health.
Used in Antioxidant Formulations:
Heraclenol is used as an antioxidant in various formulations to protect against oxidative stress and related health issues.
Used in Anti-Inflammatory Treatments:
Heraclenol is used as an anti-inflammatory agent to alleviate inflammation and associated symptoms in various conditions.

InChI:InChI=1/C16H16O6/c1-16(2,19)11(17)8-21-15-13-10(5-6-20-13)7-9-3-4-12(18)22-14(9)15/h3-7,11,17,19H,8H2,1-2H3

Upstream product

• 765316-44-7 (12R)-13-O-[β-D-apiofuranosyl-(1->6)-β-D-glucopyranosyl]heraclenol 
• 482-44-0 imperatorin 
• 35740-18-2 Prangenin 

Relevant academic research and scientific papers

Biotransformation of imperatorin by Penicillium janthinellum. Anti-osteoporosis activities of its metabolites

Imperatorin (IMP) is a major constituent of many herbal medicines and possesses anti-osteoporosis activity. The present research work aimed to study the biotransformation processes of IMP and evaluated the anti-osteoporosis activity of the transformed metabolites. Among 18 strains of filamentous fungi screened, Penicillium janthinellum AS 3.510 exhibited good capability to metabolise IMP to the new derivatives. Ten transformed products were isolated and purified, and their structures were identified accurately based on spectroscopic data. Eight metabolites (2-8 and 10) were novel and previously unreported. The major biotransformation reactions involved hydroxylation of the prenyloxy side-chain and the lactone ring-opening reaction of furocoumarin skeleton. In addition, anti-osteoporosis activities of all products (1-10) were evaluated using MC3T3-E1 cells. The results showed that products 5 and 8 had the best bioactivities in increasing MC3T3-E1 cell growth. These products could be used in future therapeutic regimens for treating osteoporosis.

Two new coumarin derivatives from the roots of Heracleum rapula

Two new coumarins, 13-O-[β-D-apiofuranosyl(1→6)-β-D- glucopyranosyl]-(12R)-heraclenol (1) and (12R,12″R)-diheraclenol (2) were isolated from the acetone extract of the fresh roots of Heracleum rapula. Their structures were determined by means of spectroscopic analysis and, in the case of compound 1, the structure elucidation was supported by acid hydrolysis. Compound 1 is a coumarin glycoside while 2 is a coumarin dimer. The inhibitory effects of 1, its aglycone (3), and 2 on rabbit platelet aggregation induced by PAF, AA and ADP were tested. Weak activities were observed for each compound with the percentages of inhibition in the range of 0.7-24.8%.

CHROMONES AND COUMARINS FROM SKIMMIA LAUREOLA

The isolation and characterisation of chromones and coumarins, including the new chromone, skimminin, from S. laureola is reported. - Key Word Index: Skimmia laureola; Rutaceae; chromones; skimminin; coumarins; linear furanocoumarins.